NeuroImage-Clinical is a premier open access journal published by Elsevier Science Ltd, dedicated to advancing the field of clinical neuroimaging and its applications in a variety of neurological disorders. With an ISSN of 2213-1582, this journal has established itself as a leading source of innovative research since its inception in 2012, now continuing through 2024. Recognized for its high impact, it occupies the top quartile (Q1) in prestigious categories such as Cognitive Neuroscience, Neurology, and Radiology, affirming its relevance in clinical and research settings. Its Scopus rankings further exemplify its significant contribution to the disciplines of Radiology and Neurology, consistently placing it among the top tiers of journals in these fields. This journal not only provides critical insights for researchers and professionals but also serves as a valuable resource for students, fostering an understanding of the complexities in neuroimaging techniques and their implications for patient care. With open access options ensuring broad dissemination of knowledge, NeuroImage-Clinical plays a pivotal role in enhancing collaboration and innovation within the global neuroscience community.

NEUROEPIDEMIOLOGY, published by KARGER, stands as a leading journal in the fields of epidemiology and neurology, with a remarkable impact reflected in its Q1 ranking in both categories for 2023. Since its inception in 1982, the journal has been pivotal in advancing our understanding of neurological disorders through a rigorous scientific lens, making significant contributions to both clinical practice and public health policies. Based in Switzerland, it attracts a global readership of researchers, healthcare professionals, and students committed to leveraging epidemiological insights to combat neurological ailments. While the journal is not open access, its valuable content—covering the full spectrum of neurological disorders, their epidemiology, and related health implications—remains accessible via institutional subscriptions. With a consistent publication schedule leading up to 2024, NEUROEPIDEMIOLOGY continues to elevate the standards of research and discussion within these dynamic fields.

NEUROLOGIST, an esteemed journal published by Lippincott Williams & Wilkins, serves as a vital resource in the fields of Neurology and Medicine. With an ISSN of 1074-7931 and an E-ISSN of 2331-2637, this journal has been dedicated to advancing the understanding of neurological disorders since its inception in 1996, with continual contributions through 2024. Achieving a respectable Q3 rank in both Medicine (miscellaneous) and Neurology (clinical), it provides an essential platform for disseminating innovative research and clinical studies. Although it is not an open-access publication, NEUROLOGIST promotes a rich exchange of ideas and findings for researchers, healthcare professionals, and students alike, helping to bridge the gaps in neurological research and practice. The journal is recognized for its commitment to enhancing clinical practice and research methodology, making it a valuable asset for anyone engaged in the dynamic field of neurology.

Current Neuropharmacology is a premier journal dedicated to advancing the field of neuropharmacology, published by Bentham Science Publishers Ltd in the United Arab Emirates. As a leader in its domain, this journal has achieved a remarkable position in 2023, with Q1 rankings across several categories including Medicine (miscellaneous), Neurology, and Pharmacology. With a robust focus on the latest research related to pharmacological treatments and their neurological implications, Current Neuropharmacology features cutting-edge studies that inform clinical practices and psychiatric care. Although not open access, the journal offers both print and electronic formats to cater to a diverse audience of researchers, healthcare professionals, and students keen on accessing vital information in neuropharmacology. Its high impact within the academia is underscored by impressive Scopus rankings, confirming its importance as a vital resource for the ongoing exploration of mental health and neurotherapeutic innovations. With an engaging scope that encompasses emerging discoveries and clinical advancements, Current Neuropharmacology continues to be an essential platform for scholarly communication in the evolving landscape of neuroscience and pharmacology.

The JOURNAL OF CHILD NEUROLOGY is a distinguished publication in the critical fields of neurology and pediatrics, published by SAGE PUBLICATIONS INC. With its ISSN 0883-0738 and E-ISSN 1708-8283, this journal has been a pivotal resource since its inception in 1986, serving the needs of researchers, clinicians, and students dedicated to advancing the understanding and treatment of neurological disorders in children. As evidenced by its impressive Q2 rankings in both Neurology (clinical) and Pediatrics, Perinatology, and Child Health, the journal has established a reputable position within the academic community, ranking in the 75th percentile for pediatrics and the 53rd percentile for clinical neurology. This periodical not only contributes to the body of knowledge in child neurology but also promotes interdisciplinary collaboration, engaging a global audience through innovative research articles and case studies. Although the journal is not open access, it remains committed to disseminating high-quality research aimed at improving pediatric health outcomes, making it an essential read for professionals and researchers dedicated to this crucial area of medicine.

Current Journal of Neurology, published by Tehran University of Medical Sciences, is an esteemed Open Access journal dedicated to advancing the field of neurology. Since its inception in 2011, the journal has provided a platform for innovative research and critical discourse in neurology and clinical neurology, with a focus on the latest advancements and methodologies. Although the journal currently holds a Q4 quartile ranking in both neurology and clinical neurology, its goal is to foster the global dissemination of knowledge and ideas relevant to the complexities of neurological disorders. Researchers, professionals, and students exploring this dynamic field will find valuable insights, as the journal aims to bridge the gap between emerging research and clinical application. Based in Tehran, Iran, the Current Journal of Neurology welcomes contributions that enhance understanding and treatment of neurological conditions, thereby promoting evidence-based practices across the globe.

EUROPEAN JOURNAL OF NEUROLOGY, published by WILEY, stands as a leading platform for the dissemination of innovative research and clinical developments in the field of neurology. With a robust impact factor and prestigious rankings, including being positioned as Q1 in both Neurology and Clinical Neurology categories, the journal plays a pivotal role in shaping neurological sciences from 1994 to 2024. Its Scopus rank highlights its importance, being in the 88th percentile for clinical neurology and 87th percentile for neuroscience. Located in the United Kingdom, the journal thrives as a vital resource for researchers, clinicians, and students dedicated to improving neurological health outcomes. Although it does not offer Open Access, its subscription-based model ensures high-quality peer-reviewed articles are accessible to a global audience, reflecting the continuous pursuit of excellence in neurological research and patient care.

Progress in Neurology and Psychiatry is a pivotal journal published by John Wiley & Sons Ltd, dedicated to advancing the fields of neurology and psychiatry. With a robust history dating back to its establishment, this esteemed journal holds a consistent Q3 ranking in 2023 across several categories including Neurology, Clinical Neurology, Psychiatry, and Mental Health, signifying its significant contribution to the scientific community. This journal serves as a vital source of knowledge and insight, publishing original research, reviews, and case studies that explore the intricacies of neurological and psychiatric disorders. Although it does not offer open access, the journal remains accessible to a wide audience through institutional subscriptions. By fostering a platform for scholarly discourse, Progress in Neurology and Psychiatry aims to bridge the gap between research and practice, ultimately enhancing the quality of care for individuals with neurological and psychiatric conditions. Researchers, clinicians, and students are encouraged to engage with the journal's comprehensive content to stay informed of the latest developments and emerging trends in these critical fields of medicine.

JAMA Neurology is a leading peer-reviewed journal published by the American Medical Association, focused on advancing the understanding and treatment of neurological disorders. With an impressive impact factor and ranked in the 99th percentile among clinical neurology journals, this publication is recognized as Q1 in its category for 2023, highlighting its significance in the field. Since its inception, the journal has provided a platform for high-quality research, clinical trials, and reviews that inform both clinicians and researchers. Operating from its headquarters in Chicago, Illinois, JAMA Neurology offers rich insights into the latest advancements in neurology, featuring articles that span a wide range of topics including neurodegenerative diseases, stroke, epilepsy, and neurocritical care. Researchers and professionals are encouraged to access the journal’s content freely, as it employs open access options to promote the dissemination of critical knowledge. As a critical resource in the field of neurology, JAMA Neurology is essential for anyone involved in this dynamic and rapidly evolving specialty.

NEUROLOGIA, an esteemed journal published by ELSEVIER ESPANA SLU, stands at the forefront of the field of neurology, with a dedicated focus on innovative research and clinical practice since its inception in 1973. As an Open Access journal since 2017, it champions the dissemination of knowledge, allowing researchers, professionals, and students alike to access cutting-edge findings in neurology without barriers. With an impressive Scopus rank of #115 in the clinical neurology category, placing it in the 71st percentile, NEUROLOGIA is categorized as Q3 in both general medicine and clinical neurology, reflecting its impact and relevance in a rapidly evolving field. Based in Barcelona, Spain, the journal's commitment to advancing understanding of neurological conditions is underscored by its rigorous peer-review process and engagement with a global audience. As it continues to publish vital research that shapes clinical practices and informs policy, NEUROLOGIA remains an integral resource for those striving to improve outcomes in neurology.